Regular Tcmp was the largest of China SXT Pharmaceuticals, Inc.’s 4 reported lines in fiscal 2026, at $1.08M — 95% of $1.14M.
| Product and Service | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Revenues Generated From Third Parties | $1.94M | $1.90M | — | — | |
| Regular Tcmp | — | — | $1.44M | $1.08M | |
| Advanced Tcmp | — | — | $258.42K | $49.52K | |
| Revenue Generated From Related Parties | $33.62K | $27.76K | $4.30K | $41 | |
| Others | — | — | $40.03K | $7.14K | |
| Total | $1.97M | $1.93M | $1.75M | $1.14M |
In fiscal 2026, which ended March 31, 2026, the 4 revenue lines China SXT Pharmaceuticals, Inc. reported in this breakdown added up to $1.14M. That was down 34.8% from $1.75M in fiscal 2025. Regular Tcmp was the largest revenue line, at $1.08M or 95.0% of the total, followed by Advanced Tcmp ($49.52K, 4.4%) and Others ($7.14K, 0.6%). Together, the two largest revenue lines made up 99.4% of this total.
Compared with fiscal 2025, every sizeable revenue line reported in both years shrank. Regular Tcmp held up best, down 25.0% to $1.08M, while Advanced Tcmp fell the most, down 80.8% to $49.52K.
Regular Tcmp (fiscal 2025), Advanced Tcmp (fiscal 2025) and Others (fiscal 2025) were first reported as separate revenue lines during this period. The table also keeps 1 revenue line that China SXT Pharmaceuticals, Inc. no longer reports, so earlier years can still be read on their original basis; use "Show 1 discontinued" beneath the table to see them. This breakdown covers every fiscal year from 2022 to 2026, as reported in China SXT Pharmaceuticals, Inc.'s annual filings.
Taizhou Jiutian Pharmaceutical Co. Ltd.[Member] was the largest of China SXT Pharmaceuticals, Inc.’s 3 reported lines in fiscal 2020, at $251.75K — 76% of $330.43K.
| Related Party | FY 2019 | FY 2020 |
|---|---|---|
| Taizhou Jiutian Pharmaceutical Co. Ltd.[Member] | $8.94K | $251.75K |
| Taizhou Su Xuan Tang Chinese Hospital Co., Ltd | $178.90K | $60.64K |
| Taizhou Su Xuan Tang Chinese Medicine Clinic | $24.32K | $18.04K |
| Total | $212.16K | $330.43K |
In fiscal 2020, which ended March 31, 2020, the 3 revenue lines China SXT Pharmaceuticals, Inc. reported in this breakdown added up to $330.43K. That was up 55.7% from $212.16K in fiscal 2019. Taizhou Jiutian Pharmaceutical Co. Ltd.[Member] was the largest revenue line, at $251.75K or 76.2% of the total, followed by Taizhou Su Xuan Tang Chinese Hospital Co., Ltd ($60.64K, 18.4%) and Taizhou Su Xuan Tang Chinese Medicine Clinic ($18.04K, 5.5%). Together, the two largest revenue lines made up 94.5% of this total.
Compared with fiscal 2019, Taizhou Jiutian Pharmaceutical Co. Ltd.[Member] grew the fastest, rising 2,715.4% to $251.75K. Taizhou Su Xuan Tang Chinese Hospital Co., Ltd fell the most, down 66.1% to $60.64K.
This breakdown covers every fiscal year from 2019 to 2020, as reported in China SXT Pharmaceuticals, Inc.'s annual filings.
China SXT Pharmaceuticals, Inc. (SXTC) breaks its revenue down by revenue line. In fiscal 2026, its largest revenue line was Regular Tcmp, with $1.08M or 95.0% of the total, followed by Advanced Tcmp at $49.52K (4.4%).
Regular Tcmp was China SXT Pharmaceuticals, Inc.'s largest revenue line in fiscal 2026, with $1.08M in revenue, 95.0% of the $1.14M reported across its 4 revenue lines.
Of the China SXT Pharmaceuticals, Inc. revenue lines reported in both fiscal 2019 and fiscal 2020, and making up at least 2% of the total, Taizhou Jiutian Pharmaceutical Co. Ltd.[Member] grew the fastest, rising 2,715.4% from $8.94K to $251.75K.
Every figure is taken from China SXT Pharmaceuticals, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2022 to 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.